Simcere to acquire manufacturing license for cholesterol drug from Tianjin

Simcere Pharmaceutical Group, a developer of branded generic and proprietary pharmaceuticals, has signed an agreement to acquire the manufacturing license in China of rosuvastatin from Tianjin Tianda Pharmaceutical.

The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda.

Rosuvastatin was first marketed by Astrazeneca as Crestor in 2003 and is an effective statin to treat high cholesterol and related conditions, said Simcere. Upon completion of the acquisition, Simcere will start manufacturing rosuvastatin.